Dnazyme-Based Therapeutics for Cancer Treatment

References

• Breaker RR , JoyceGF. A DNA enzyme that cleaves RNA. Chem. Biol.1 (4), 223–229 (1994).
   PubMedGoogle Scholar
• Santoro SW , JoyceGF. A general purpose RNA-cleaving DNA enzyme. Proc. Natl Acad. Sci. USA94 (9), 4262–4266 (1997).
   PubMed Web of Science ®Google Scholar
• Breaker RR , JoyceGF. A DNA enzyme with Mg(2+)-dependent RNA phosphoesterase activity. Chem. Biol.2 (10), 655–660 (1995).
   PubMedGoogle Scholar
• Santoro SW , JoyceGF. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry37 (38), 13330–13342 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang L , YangL, LiJJ, SunL. Potential use of nucleic acid-based agents in the sensitization of nasopharyngeal carcinoma to radiotherapy. Cancer Lett.323 (1), 1–10 (2012).
   PubMed Web of Science ®Google Scholar
• Bhindi R , FahmyRG, LoweHCet al. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am. J. Pathol.171 (4), 1079–1088 (2007).
   PubMed Web of Science ®Google Scholar
• Dass CR , SaravolacEG, LiY, SunLQ. Cellular uptake, distribution, and stability of 10–23 deoxyribozymes. Antisense Nucleic Acid Drug Dev.12 (5), 289–299 (2002).
   PubMedGoogle Scholar
• Yang L , XiaoL, MaXet al. Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma. Cancer Biol. Ther.8 (4), 366–371 (2009).
   PubMed Web of Science ®Google Scholar
• Yang L , HeJT, GuanH, SunYD. Akt1 inhibitory DNAzymes inhibit cell proliferation and migration of thyroid cancer cells. Asian Pac. J. Cancer Prev.14 (4), 2571–2575 (2013).
   PubMedGoogle Scholar
• Wang X , ZhangL, DingNet al. Identification and characterization of DNAzymes targeting DNA methyltransferase I for suppressing bladder cancer proliferation. Biochem. Biophys. Res. Commun.461 (2), 329–333 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang G , DassCR, SumithranE, Di GirolamoN, SunLQ, KhachigianLM. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J. Natl Cancer Inst.96 (9), 683–696 (2004).
   PubMedGoogle Scholar
• Cai H , SantiagoFS, Prado-LourencoLet al. DNAzyme targeting c-Jun suppresses skin cancer growth. Sci. Transl Med.4 (139), 139ra182 (2012).
   Web of Science ®Google Scholar
• Cho EA , MoloneyFJ, CaiHet al. Safety and tolerability of an intratumorally injected DNAzyme, dz13, in patients with nodular basal-cell carcinoma: a Phase 1 first-in-human trial (discover). Lancet381 (9880), 1835–1843 (2013).
   PubMed Web of Science ®Google Scholar
• Dass CR , FriedhuberAM, KhachigianLM, DunstanDE, ChoongPF. Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biol. Ther.7 (7), 1033–1036 (2008).
   PubMed Web of Science ®Google Scholar
• Dass CR , GallowaySJ, ClarkJC, KhachigianLM, ChoongPF. Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Bio. Ther.7 (8), 1297–1301 (2008).
   PubMed Web of Science ®Google Scholar
• Dass CR , KhachigianLM, ChoongPF. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol. Cancer Ther.7 (7), 1909–1912 (2008).
   PubMed Web of Science ®Google Scholar
• Yu X , YangL, CairnsMJet al. Chemosensitization of solid tumors by inhibition of bcL-xL expression using DNAzyme. Oncotarget5 (19), 9039–9048 (2014).
   PubMedGoogle Scholar
• Zhang M , SunYF, LuoS. Ani-survivin DNAzymes inhibit cell proliferation and migration in breast cancer cell line MCF-7. Asian Pac. J. Cancer Prev.13 (12), 6233–6237 (2012).
   PubMedGoogle Scholar
• Zhang M , DrummenGP, LuoS. Anti-insulin-like growth factor-IIP3 DNAzymes inhibit cell proliferation and induce caspase-dependent apoptosis in human hepatocarcinoma cell lines. Drug Des. Devel. Ther.7, 1089–1102 (2013).
   PubMed Web of Science ®Google Scholar
• Yang L , ZengW, LiD, ZhouR. Inhibition of cell proliferation, migration and invasion by DNAzyme targeting MMP-9 in A549 cells. Oncol. Rep.22 (1), 121–126 (2009).
   PubMed Web of Science ®Google Scholar
• Hallett MA , TengB, HasegawaH, SchwabLP, SeagrovesTN, PourmotabbedT. Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer. Breast Cancer Res.15 (1), R12 (2013).
   PubMed Web of Science ®Google Scholar
• Hallett MA , DalalP, SweatmanTW, PourmotabbedT. The distribution, clearance, and safety of an anti-MMP-9 DNAzyme in normal and MMTV-PyVT transgenic mice. Nucleic Acid Ther.23 (6), 379–388 (2013).
   PubMed Web of Science ®Google Scholar
• Fahmy RG , DassCR, SunLQ, ChestermanCN, KhachigianLM. Transcription factor EGR-1 supports FGF-1 dependent angiogenesis during neovascularization and tumor growth. Nat. Med.9 (8), 1026–1032 (2003).
   PubMed Web of Science ®Google Scholar
• Marin-Ramos NI , AlonsoD, Ortega-GutierrezSet al. New inhibitors of angiogenesis with antitumor activity in vivo. J. Med. Chem.58 (9), 3757–3766 (2015).
   PubMed Web of Science ®Google Scholar
• Folkman J . Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg.175 (3), 409–416 (1972).
   PubMed Web of Science ®Google Scholar
• Zhang L , GasperWJ, StassSA, IoffeOB, DavisMA, MixsonAJ. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res.62 (19), 5463–5469 (2002).
   PubMed Web of Science ®Google Scholar
• Shen L , ZhouQ, WangYet al. Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme. Mol. Med.19, 377–386 (2013).
   PubMed Web of Science ®Google Scholar
• Cairns MJ , HopkinsTM, WitheringtonC, WangL, SunLQ. Target site selection for an RNA-cleaving catalytic DNA. Nat. Biotechnol.17 (5), 480–486 (1999).
   PubMed Web of Science ®Google Scholar
• Lu ZX , YeM, YanGRet al. Effect of EBV LMP 1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther.12 (7), 647–654 (2005).
   PubMed Web of Science ®Google Scholar
• Wo JE , WuXL, ZhouLF, YaoHP, ChenLW, DenninRH. Effective inhibition of expression of hepatitis B virus genes by DNAzymes. World J. Gastroenterol.11 (23), 3504–3507 (2005).
   PubMed Web of Science ®Google Scholar
• Hou W , WoJE, LiMW, LiuKZ. In vitro cleavage of hepatitis b virus C mRNA by 10–23 DNA enzyme. Hepatobiliary Pancreat. Dis. Int.4 (4), 573–576 (2005).
   PubMedGoogle Scholar
• Wakisaka N , PaganoJS. Epstein–Barr virus induces invasion and metastasis factors. Anticancer Res.23 (3a), 2133–2138 (2003).
   PubMed Web of Science ®Google Scholar
• Kilger E , KieserA, BaumannM, HammerschmidtW. Epstein–Barr virus-mediated b-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J.17 (6), 1700–1709 (1998).
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG , YoungLS. Activation of the cJun n-terminal kinase (JNK) pathway by the Epstein–Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene16 (13), 1731–1742 (1998).
   PubMed Web of Science ®Google Scholar
• Gires O , KohlhuberF, KilgerEet al. Latent membrane protein 1 of Epstein–Barr virus interacts with JAK3 and activates STAT proteins. EMBO J.18 (11), 3064–3073 (1999).
   PubMed Web of Science ®Google Scholar
• Tao YG , TanYN, LiuYPet al. Epstein–Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner. Cell Signal.16 (7), 781–790 (2004).
   PubMed Web of Science ®Google Scholar
• Ke X , YangYC, HongSL. Ebv-lmp1-targeted DNAzyme restrains nasopharyngeal carcinoma growth in a mouse C666–1 xenograft model. Med. Oncol.28 (Suppl. 1), S326–S332 (2011).
   PubMedGoogle Scholar
• Yang L , LuZ, MaX, CaoY, SunLQ. A therapeutic approach to nasopharyngeal carcinomas by DNAzymes targeting EBA LMP-1 gene. Molecules15 (9), 6127–6139 (2010).
   PubMed Web of Science ®Google Scholar
• Sun L . EBV-LMP-targeted DNAzyme induces DNA damage and causes cell cycle arrest in LMP1-positive nasopharyngeal carcinoma cells. Int. J. Oncol. (43) 5, 1541–1548 (2013).
   PubMed Web of Science ®Google Scholar
• Ma X , YangL, XiaoLet al. Down-regulation of ebv-lmp1 radio-sensitizes nasal pharyngeal carcinoma cells via NF-kappaB regulated atm expression. PLoS ONE6 (11), e24647 (2011).
   PubMed Web of Science ®Google Scholar
• Lu ZX , MaXQ, YangLFet al. DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett.265 (2), 226–238 (2008).
   PubMed Web of Science ®Google Scholar
• Cao Y , YangL, JiangWet al. Therapeutic evaluation of Epstein–Barr virus-encoded latent membrane protein-1 targeted DNAzyme for treating of nasopharyngeal carcinomas. Mol. Ther.22 (2), 371–377 (2014).
   PubMed Web of Science ®Google Scholar
• Finkel E . DNA cuts its teeth – as an enzyme. Science286 (5449), 2441–2442 (1999).
   PubMed Web of Science ®Google Scholar
• Sioud M , LeirdalM. Design of nuclease resistant protein kinase calpha DNA enzymes with potential therapeutic application. J. Mol. Biol.296 (3), 937–947 (2000).
   PubMed Web of Science ®Google Scholar
• Goodchild J . Hammerhead ribozymes: biochemical and chemical considerations. Curr. Opin. Mol. Ther.2 (3), 272–281 (2000).
   PubMedGoogle Scholar
• Shimayama T , NishikawaS, TairaK. Generality of the nux rule: kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes. Biochemistry34 (11), 3649–3654 (1995).
   PubMed Web of Science ®Google Scholar
• Kuwabara T , WarashinaM, TanabeT, TaniK, AsanoS, TairaK. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of Bcr–Abl chimeric l6 (b2a2) mRNA. Nucleic Acids Res.25 (15), 3074–3081 (1997).
   PubMed Web of Science ®Google Scholar
• Fokina AA , StetsenkoDA, FrancoisJC. DNA enzymes as potential therapeutics: rowards clinical application of 10–23 DNAzymes. Expert Opin. Biol. Ther.15 (5), 689–711 (2015).
   PubMed Web of Science ®Google Scholar
• Tan ML , ChoongPF, DassCR. DNAzyme delivery systems: getting past first base. Expert Opin. Drug Deliv.6 (2), 127–138 (2009).
   PubMed Web of Science ®Google Scholar